Pierre Fabre Pharmaceuticals and Atara Biotherapeutics resubmitted Ebvallo (tabelecleucel) to the FDA after two prior rejections, seeking approval for EBV+ PTLD following transplant. The companies say the updated submission aligns with FDA expectations on the clinical path, while they characterize earlier disagreements as driven by shifting regulator positions on trial interpretability. In parallel, regulatory attention remains focused on both clinical evidence and manufacturing quality. Earlier FDA feedback included concern that the single-arm pivotal Phase 3 ALLELE study was insufficient for a BLA, even after the partners addressed GMP issues and reported no new safety concerns. Analysts cited in the reporting suggested the resubmission could land as a Class 2 BLA resubmission with a target action date into March 2027, depending on the FDA’s review scope. The resubmission keeps one of the most closely watched U.S. cell therapy pathways for a rare post-transplant indication moving forward. Separately, the same regulatory resubmission theme is echoed across other late-stage programs in this issue, highlighting that FDA decision timelines increasingly hinge on evidence-package design and regulator alignment as much as on raw endpoint magnitude.